accountthe most exciting in the industry��� and should help it outpace profit growth at drugmakers including Pfizer Inc., Merck & Co. and Bristol-Myers Squibb Co., said Jami Rubin, a Goldman Sachs Group Inc. analyst in New York. The prospects helped pushed J&J...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to J&J AIDS Pill Signals $9B in Revenue to Ease Recalls
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account